2014
The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer
Henick BS, Herbst RS, Goldberg SB. The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer. Expert Opinion On Therapeutic Targets 2014, 18: 1407-1420. PMID: 25331677, DOI: 10.1517/14728222.2014.955794.Peer-Reviewed Original ResearchConceptsPD-1 pathwayEarly clinical trialsClinical trialsTumor typesDeath-1 pathway inhibitorsPD-1 pathway inhibitionImmune escape mechanismsOngoing clinical trialsEarly-stage cancerTreatment of cancerCure rateLikely respondersCancer immunotherapyPreclinical dataAntineoplastic effectsTherapeutic targetPathway inhibitionPathway inhibitorCancer typesBiological rationaleCancer treatmentMonoclonal antibodiesEscape mechanismsUpcoming trialsTrials
2012
L4.1 Evolution of Battle Trials at Md Anderson Cancer Center
Hong W, Kim E, Herbst R, Papadimitrakopoulou V, Gold K, Wistuba I, Lee J, Lippman S. L4.1 Evolution of Battle Trials at Md Anderson Cancer Center. Annals Of Oncology 2012, 23: v7. DOI: 10.1016/s0923-7534(20)31272-2.Peer-Reviewed Original ResearchNational Lung Screening TrialLung cancerBATTLE TrialHigh riskLow-dose helical computed tomographyLung Cancer Elimination (BATTLE) trialMolecular driversMD Anderson Cancer CenterUntreated lung cancerAdvanced lung cancerFive-year survivalAdvanced cancer settingLung cancer patientsCore needle biopsyLung cancer developmentNovel trial designsAnderson Cancer CenterPatient treatment selectionFresh tumor biopsiesHelical computed tomographyEarly-stage cancerNumber one causeOptimal drug combinationsRefractory patientsPrevention setting